[Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review]. 1996

D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
Centro de Salud de Galdakao, Vizcaya.

UI MeSH Term Description Entries
D009553 Nimodipine A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. Admon,Bay e 9736,Brainal,Calnit,Kenesil,Modus,Nimodipin Hexal,Nimodipin-ISIS,Nimodipino Bayvit,Nimotop,Nymalize,Remontal,Bayvit, Nimodipino,Hexal, Nimodipin,Nimodipin ISIS,e 9736, Bay
D010889 Piracetam A compound suggested to be both a nootropic and a neuroprotective agent. 2-Pyrrolidone-N-Acetamide,Avigilen,Axonyl,Cerebroforte,Cerepar N,Ciclofalina,Cuxabrain,Dinagen,Gabacet,Geram,Memo-Puren,Nootrop,Nootropil,Nootropyl,Normabraïn,Piracebral,Piracetam AbZ,Piracetam-RPh,Piracetrop,Pirazetam,Pyracetam,Pyramem,Sinapsan,UCB-6215,Memo Puren,Piracetam RPh,UCB 6215,UCB6215
D003704 Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Senile Paranoid Dementia,Amentia,Familial Dementia,Amentias,Dementia, Familial,Dementias,Dementias, Familial,Dementias, Senile Paranoid,Familial Dementias,Paranoid Dementia, Senile,Paranoid Dementias, Senile,Senile Paranoid Dementias
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D013619 Tacrine A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tetrahydroaminoacridine,1,2,3,4-Tetrahydro-9-acridinamine,1,2,3,4-Tetrahydroaminoacridine,9-Amino-1,2,3,4-Tetrahydroacridine,Cognex,Romotal,THA,Tacrine Hydrochloride,Tenakrin
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D018697 Nootropic Agents Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. Anti-Dementia Agent,Antidementia Agent,Cognitive Enhancer,Cognitive Enhancers,Nootropic,Nootropic Agent,Nootropic Drug,Procognitive Agent,Anti-Dementia Agents,Antidementia Agents,Nootropic Drugs,Nootropics,Procognitive Agents,Agent, Anti-Dementia,Agent, Antidementia,Agent, Nootropic,Agent, Procognitive,Agents, Anti-Dementia,Agents, Antidementia,Agents, Nootropic,Agents, Procognitive,Anti Dementia Agent,Anti Dementia Agents,Drug, Nootropic,Drugs, Nootropic,Enhancer, Cognitive,Enhancers, Cognitive

Related Publications

D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
September 2020, Pakistan journal of pharmaceutical sciences,
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
September 1998, Drugs of today (Barcelona, Spain : 1998),
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
January 2005, Pharmazie in unserer Zeit,
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
July 1996, Journal of geriatric psychiatry and neurology,
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
October 1997, Journal of the American Geriatrics Society,
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
January 1989, European neurology,
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
February 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
April 1997, Pharmacology, biochemistry, and behavior,
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
August 2016, International wound journal,
D Ojer Tsakiridu, and J O Dosantos Hernández, and J Larrabe Medina, and J I Sánchez Casado, and A Sologuren Echenagusia
July 1998, Neurology,
Copied contents to your clipboard!